Forxiga

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Type 2 DiabetesType 1 DiabetesDiabetes MellitusMembranous NephropathyGlomerulonephritis

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

1

Forxiga

AstraZeneca

Approved

32

Byetta

AstraZeneca

Preclinical

553

Jardiance

Boehringer Ingelheim

Preclinical

314

Glargine

Eli Lilly

Preclinical

85

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

26

Aurlumyn

BBTG International Inc.

Preclinical

17

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

18

Inderal

WWyeth-Lederle Vaccines

Preclinical

19

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

110

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1Show 17 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Type 1 Diabetes4 trials

Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes

Completed·SSteno Diabetes Center Copenhagen·Phase 4·NCT04193566·30 enrolled

Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin

Not yet recruiting·SSt Vincent's Hospital Melbourne·Phase 2·NCT07225465·115 enrolled

Effects of Dapagliflozin on Hormonal Glucose Homeostasis in Type 1 Diabetes

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 3·NCT04035031·13 enrolled

Show 1 more trial

Dapagliflozin in Physical Exercise in Type 1 Diabetes

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 3·NCT04049110·39 enrolled

Type 2 Diabetes3 trials

Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey

Completed·AstraZeneca··NCT03407196·1,683 enrolled

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

Completed·PPopulation Health Research Institute·Phase 4·NCT02561130·154 enrolled

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

Completed·DDong-A ST Co., Ltd.·Phase 4·NCT05743907·231 enrolled

Diabetes Mellitus1 trial

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Withdrawn·EEMS·Phase 3·NCT03766750

Tics1 trial

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

Completed·DDong-A ST Co., Ltd.·Phase 1·NCT04473417·60 enrolled

Dapagliflozin1 trial

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Completed·AstraZeneca·Phase 1·NCT03138356·126 enrolled

2 more indications

Glomerulonephritis1 trial

Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous

Not yet recruiting·CCentre Hospitalier Universitaire de Nice·Phase 2·NCT07096986·20 enrolled

Unspecified1 trial

forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

Terminated·AstraZeneca··NCT01944618·5,000 enrolled

Details

Drug Info

Related News